With respect to patients with HeFH and homozygous FH who are challenged with lifelong CV disease risk burden due to genetic risk, what role do you believe PCSK9 inhibitors should play, especially in younger patient populations?

With respect to patients with HeFH and homozygous FH who are challenged with lifelong CV disease risk burden due to genetic risk, what role do you believe PCSK9 inhibitors should play, especially in younger patient populations?

CLICK HERE FOR CME CREDIT

With respect to patients with HeFH and homozygous FH who are challenged with lifelong CV disease risk burden due to genetic risk, what role do you believe PCSK9 inhibitors should play, especially in younger patient populations?

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Ulf Landmesser MD, FESC

Ulf Landmesser MD, FESC

Professor of Cardiology
Medical Director, Department of Cardiology
Charite University Hospital
Berlin, Germany